TMEFF2 and neoplasm: Dose escalation of the anti-TENB2 predose had a dose-dependent effect on 111In-ADC uptake in tumor, with competitive inhibition of binding resulting in lower uptake of radiolabeled ADC as the predosed mAb is increased, particularly at 3 mg/kg (Figure 4D).